Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: A randomized phase II trial

Annals of Oncology

Volumn 16, Issue 2, 2005, Pages 294-299

  Pectasides, D ^a,c   Pectasides, M ^a   Farmakis, D ^b   Kostopoulou, V ^b   Nikolaou, M ^b   Gaglia, A ^b   Koumpou, M ^b   Mylonakis, N ^b   Xiros, N ^a   Economopoulos, T ^a   Raptis, S A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

Docetaxel; Irinotecan; Non small cell lung cancer; Platinum refractory; Salvage regimen; Second line chemotherapy

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; STEROID;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG ERUPTION; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HEART INFARCTION; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; PERCEPTION DISORDER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; STATISTICAL ANALYSIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; UNDIFFERENTIATED CARCINOMA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 20044387595     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi053     Document Type: Article

References (28)

1. Georgoulias VA. Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer. Lung Cancer 2002; 38: 61-66.
2. Fossella FV, Lee JS, Hong WK. Management strategies for recurrent non-small cell lung cancer. Semin Oncol 1997; 24: 455-462.
3. Fossella FV, Lee JS, Berille J et al. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 1995; 22: 22-29.
4. Burris H, Eckardt J, Fields S et al. Phase II trials of Taxotere in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 1993; 12: 335a (Abstr 1116).
5. Fossella FV, Lee JS, Shin DM et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995; 13: 645-651.
6. Gandara DR, Vokes E, Green M et al. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 2000; 18: 131-135.
7. Robinet G, Thomas P, Perol M et al. Phase II study of Taxotere® (docetaxel) in advanced or metastatic non small cell lung cancer (NSCLC) previously treated with platinum. Ann Oncol 1996; 5: 96-97 (Abstr 458P).
8. Robinet G, Kleisbauer JP, Thomas P et al. Phase II study of docetaxel (Taxotere®) in first- and second-line NSCLC. Proc Am Soc Clin Oncol 1997; 16: 480a (Abstr 1726).
9. Mattson K, Le Chevalier T, Stupp R et al. Preliminary report of a phase II study of docetaxel (Taxotere®) in locally advanced or metastatic non-small cell lung cancer (NSCLC). Ann Oncol 1996; 5: 429a (Abstr 429P).
10. Le Chevalier T. Docetaxel: meeting the challenge of non-small cell lung cancer management. Anticancer Drugs 1995; 6: 13-17.
11. Yokoyama A, Kurita Y, Watanabe K et al. Early phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer. Docetaxel Cooperative Study Group for Lung Cancer. Gan To Kagaku Ryoho 1994; 21: 2609-2616.
12. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small-Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354-2362.
13. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
14. Shimada Y, Rothenberg M, Hilsenbeck SG et al. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 1994; 5: 202-206.
15. Tamura K, Takada M, Kawase I et al. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res 1997; 88: 218-223.
16. Baker L, Khan R, Lynch T et al. Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1997; 16: 461a (Abstr 1658).
17. Negoro S, Fukuoka M, Niitani H et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. Gan To Kagaku Ryoho 1991; 18: 1013-1019.
18. Fukuoka M, Nittani H, Suzuki A et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992; 10: 16-20.
19. Sanchez R, Esteban E, Palacio I et al. Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes. Invest New Drugs 2003; 21: 459-463.
20. Masuda N, Negoro S, Kudoh S et al. Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer. J Clin Oncol 2000; 18: 2996-3003.
21. Chou TC, Motzer RJ, Tong Y et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-1524.
22. Taron M, Plasencia C, Abad A et al. Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines. Invest New Drugs 2000; 18: 139-147.
23. Kaufmann SH, Peereboom D, Buckwalter CA et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996; 88: 734-741.
24. Couteau C, Risse ML, Ducreux M et al. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. J Clin Oncol 2000; 18: 3545-3552.
25. Font A, Sanchez JM, Rosell R et al. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors. Lung Cancer 2002; 37: 213-218.
26. Rich R, Argiris A, Peccerillo K et al. Phase I dose escalation trial of weekly docetaxel (D) plus irinotecan (I) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 1999; 18: 524a (Abstr 868).
27. Font A, Sanchez JM, Taron M et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diposphate glucoronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs 2003; 21: 435-443.
28. Vernejoux JM, Thomas P, Robinet G et al. Weekly schedule of docetaxel (Taxotere®)-irinotecan (Campto®) in metastatic non small cell lung cancer (NSCLC): results of phase I trial. Proc Am Soc Clin Oncol 2002; 21: 233b (Abstr 2750).